Omega Diagnostics
Alva
About Omega Diagnostics
Omega Diagnostics Group PLC, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits that are used in the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test. This segment’s principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Disease segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases, such as syphilis, tuberculosis, dengue fever, Chagas disease, and malaria. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its diagnostic kits and systems to hospitals, blood banks, clinics, and laboratories through distributors in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $15.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2022)
- Ticker: lse:ODX
- Website: omegadiagnostics.com
- Phone: +44 1259 763030
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/omega-diagnostics-223327 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.